[HTML][HTML] Integration of artificial intelligence in lung cancer: Rise of the machine
C Ladbury, A Amini, A Govindarajan… - Cell Reports …, 2023 - cell.com
The goal of oncology is to provide the longest possible survival outcomes with the
therapeutics that are currently available without sacrificing patients' quality of life. In lung …
therapeutics that are currently available without sacrificing patients' quality of life. In lung …
[HTML][HTML] Artificial intelligence and lung cancer: impact on improving patient outcomes
Simple Summary In this comprehensive review, we aimed to summarize the advances made
by artificial intelligence in the field of lung cancer screening, diagnosis, and management …
by artificial intelligence in the field of lung cancer screening, diagnosis, and management …
[HTML][HTML] Clinical network systems biology: traversing the cancer multiverse
I Mambetsariev, J Fricke, SB Gruber, T Tan… - Journal of Clinical …, 2023 - mdpi.com
In recent decades, cancer biology and medicine have ushered in a new age of precision
medicine through high-throughput approaches that led to the development of novel targeted …
medicine through high-throughput approaches that led to the development of novel targeted …
[HTML][HTML] Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine …
MR Sayer, I Mambetsariev, KH Lu, CW Wong… - Frontiers in …, 2023 - frontiersin.org
Introduction Immune checkpoint inhibitors (ICIs) produce a broad spectrum of immune-
related adverse events (irAEs) affecting various organ systems. While ICIs are established …
related adverse events (irAEs) affecting various organ systems. While ICIs are established …
[HTML][HTML] Selpercatinib and pralsetinib induced chylous ascites in RET-rearranged lung adenocarcinoma: a case series
J Fricke, J Wang, N Gallego, I Mambetsariev, P Kim… - Clinical Lung Cancer, 2023 - Elsevier
Clinical Practice Points• The selective RET-TKIs, ie, selpercatinib and pralsetinib are
effective against RET fusions in patients with NSCLC.• Chylous ascites (CA) is an extremely …
effective against RET fusions in patients with NSCLC.• Chylous ascites (CA) is an extremely …
[HTML][HTML] Characterization of KRAS Mutational Regression in Oligometastatic Patients
A Ottaiano, RP de Vera d'Aragona, AM Trotta… - Frontiers in …, 2022 - frontiersin.org
Background We previously reported rare regressive genetic trajectories of KRAS pathogenic
mutations as a specific hallmark of the genuine oligometastatic status in colorectal cancer …
mutations as a specific hallmark of the genuine oligometastatic status in colorectal cancer …
[HTML][HTML] Clinical and Immunologic Characteristics of Non-Hematologic Cancers in Patients with Inborn Errors of Immunity
Simple Summary Comprehensive studies on non-hematologic tumors in patients with inborn
errors of immunity are scarce. Using a well-established registry of patients with long-term …
errors of immunity are scarce. Using a well-established registry of patients with long-term …
[HTML][HTML] Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
J Peng, S Fang, M Li, Y Liu, X Liang, Z Li… - Open Life …, 2023 - degruyter.com
The aim of this study is to investigate certain genetic features of intrahepatic
cholangiocarcinoma (ICCA). A total of 12 eligible ICCA patients were enrolled, and tumor …
cholangiocarcinoma (ICCA). A total of 12 eligible ICCA patients were enrolled, and tumor …
Implications of Evolutionary Dynamics for Cancer Treatment and Prevention
RC Jackson - Evolutionary Dynamics of Malignancy: The Genetic and …, 2023 - Springer
Understanding the evolutionary dynamics of malignancy has implications for prevention,
diagnosis, and treatment of cancer. Cancer incidence can be partially prevented by …
diagnosis, and treatment of cancer. Cancer incidence can be partially prevented by …